As with other drugs, Darzalex Faspro (daratumumab/hyaluronidase-fihj) can cause side effects, such as upper respiratory tract infection. If you’re not able to ...

Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients. It has already been submitted for approval in the EU.

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

Analysts think the shorter treatment of Darzalex Faspro time could become a particularly important advantage over the established formulation during the coronavirus pandemic, when getting access ...

Per the deal terms, Dr. Reddy’s (NYSE:RDY) and Henlius (OTCPK:SGBCF) will jointly develop the latter’s monoclonal antibody injection HLX15 as a biosimilar for Darzalex and Darzalex Faspro in ...

However, Darzalex Faspro’s subcutaneous administration is even more efficient. While Sanofi is currently evaluating the safety and efficacy of isatuximab administered subcutaneously, we believe ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.

Listed below are the charts and positions for Darzalex / Faspro in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Darzalex / Faspro. GlobalData provides trusted ...

Apart from this, DARZALEX FASPRO is a subcutaneous (SC) formulation that combines daratumumab, a CD38-targeting cytolytic antibody, with hyaluronidase, an enzyme that aids in drug absorption.